FDFei Dong

Fei Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fei Dong has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Lynette M. Sholl

    From the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Lechner, Rai, Rojas-Rudilla, Sholl, Dong)

    5 shared publications
  • Agoston T. Agoston

    Department of Pathology, Brigham and Women’s Hospital, Boston, USA

    2 shared publications
  • Amitabh Srivastava

    Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Now with Department of Pathology, Memorial Sloan Kettering Cancer Center, New York

    2 shared publications
  • Christopher D. M. Fletcher

    Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

    2 shared publications
  • Cloud P. Paweletz

    The Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts(Kuang, Paweletz)

    2 shared publications
  • Danielle K. Manning

    Department of Pathology, Brigham and Women’s Hospital, Boston, USA

    2 shared publications

Latest Publications

  • Histological and molecular characterization of lateral extension in papillary urothelial carcinoma: implications for classification and management

    by Richard R Pacheco, Dylan J Peterson, Alan Thong, Eugene Shkolyar, Joseph C Liao, Guolan Lu, Kris B Prado, Fei Dong, Emily Chan

    Introduction: Lateral extension (LE) in urinary bladder papillary urothelial carcinoma (PUC) refers to the phenomenon where atypical urothelium is seen extending laterally in a flat configuration from the base of the papillary tumour. LE is recognized but poorly defined, resulting in inconsistent diagnoses and interpretations amongst pathologists, ranging from atypia to carcinoma in situ (CIS). Herein, we aim to better characterize LE in high‐grade PUC, utilizing en bloc transurethral resection specimens. Methods: We reviewed 37 en bloc specimens from 25 patients and performed comprehensive morphological, molecular and immunohistochemical characterization of PUC and LE components. Results: Three morphological patterns were seen: no LE ( n = 24), LE with lower‐grade cytomorphology compared to adjacent PUC (lower‐grade LE, n = 10), and LE with cytomorphology similar to adjacent PUC (higher‐grade LE, n = 3). Mean LE length was 4.7 mm (range 1.5–10.8 mm). LE extended to mucosal margins in 12/13 (92%). Differential next‐generation sequencing was performed on paired PUC and adjacent LE components in 11/13 tumours with LE. In 9/11 (82%), LE and PUC showed at least a subset of shared pathogenic/likely pathogenic alterations, supporting clonality between the two components; in five tumours, there were additional alterations specific to PUC, with and without LE‐specific alterations. Immunohistochemical staining for CK20 and p53 showed LE with abnormal CK20 in all 11/11 tumours and aberrant p53 in 3/11 (27%). PUC and LE showed concordant p53 staining patterns in 10/11 (91%) and CK20 in only 6/11 (55%) specimens. Conclusion: We find that LE can extend at least 1 cm from the base of PUC, suggesting consideration for wider resection margins if complete surgical resection is desired. Additionally, LE is clonally related to PUC in most cases, albeit with heterogeneous relationships, as evidenced by both molecular and immunohistochemical findings. Notably, LE can show immunohistochemical findings similar to those commonly reported for CIS. Recognition of LE may improve diagnostic consistency and reduce overdiagnosis of CIS in the setting of prior papillary tumours.

  • Comparison of DNA- and RNA-Based Mutation Testing for Non–Small Cell Lung Cancer

    by Igor Odintsov, David D.W. Twa, Eula Fung, Tsoyu Chiang, Chandler Ho, Gregory W. Charville, Henning Stehr, Fei Dong

  • Preanalytical Histology Review Improves POLE Mutation Detection in Endometrial Carcinomas

    by Hehua Huang, Sara Hartinger, Rachel L.P. Geisick, Chandler Ho, Fei Dong


  • Open Access

    Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer

    by Adam Lechner, Anooja Rai, Vanesa Rojas-Rudilla, Yanan Kuang, Cloud P. Paweletz, Lynette M. Sholl, Fei Dong

    Context: Droplet digital polymerase chain reaction (ddPCR) is a sensitive method to detect common pathogenic EGFR mutations in non–small cell lung cancer. Although targeted assays have not been specifically designed to detect them, uncommon EGFR mutations have been linked to response to targeted therapy. Objective: To describe atypical ddPCR patterns that correspond to uncommon but clinically actionable EGFR mutations. Design: A cohort of 1134 consecutive non–small cell lung cancers that underwent targeted next-generation sequencing was reviewed. Uncommon EGFR mutations involving probe binding sites were evaluated by ddPCR. Results: Two hundred fifty-five of 1134 cancers (22.5%) harbored pathogenic EGFR mutations. One hundred eighty-six of 255 (72.9%) had canonical EGFR exon 19 deletion or exon 21 p.L858R variants designed for detection by ddPCR. An additional 25 of 255 cases (9.8%) had uncommon EGFR mutations within the probe-binding site, including 1 case with concurrent uncommon mutations in both exon 19 and exon 21. These mutations included uncommon EGFR exon 19 deletions (n = 6), EGFR exon 19 substitutions p.L747P (n = 3) and p.L747A (n = 1), dinucleotide substitutions leading to EGFR p.L858R (n = 5), EGFR exon 21 substitutions p.K860I (n = 1) and p.L861Q (n = 9), and EGFR p.[L858R;K860I] (n = 1). Droplet digital polymerase chain reaction generated atypical but reproducible signal for each of these uncommon variants. Conclusions: Droplet digital polymerase chain reaction analysis of uncommon pathogenic EGFR variants can yield unique and reproducible results. Recognition of atypical patterns in EGFR ddPCR testing can prompt confirmatory molecular testing and aid appropriate targeted therapy selection for patients with non–small cell lung cancer.


  • Mutational Signatures in Cancer

    by Fei Dong, Kurtis D. Davies


  • The success rates of clinical cancer next-generation sequencing based on pathologic diagnosis: Experience from a single academic laboratory

    by Katherine Latham, Fei Dong

    This article aims to establish the relationship between pathologic diagnosis and the rate of success in cancer next-generation sequencing testing. Clinical next-generation sequencing results performed for solid tumors were reviewed. The rate of success was analyzed in the context of tumor type and accompanying variables. Out of 683 total specimens, 533 (78.0%) underwent successful sequencing. The rate of success was 91.8% for ovarian carcinomas, 87.5% for lung non–small cell carcinomas, 82.0% for colorectal adenocarcinomas, 78.3% for melanomas, 75.9% for breast carcinomas, and 64.7% for pancreatic adenocarcinomas. For specimens that successfully underwent sequencing, pancreatic adenocarcinomas had the lowest median tumor proportion and somatic RAS and TP53 mutation allele fractions compared with other tumor types. Cytology specimens had a 33.3% success rate for pancreatic adenocarcinomas (5 of 15) and a 93.3% success rate for lung carcinomas (14 of 15). Compared with tissue from primary sites, tissue from metastatic sites showed a higher success rate for pancreatic adenocarcinomas and lower success rates for colorectal adenocarcinomas and melanomas. The success rate of cancer next-generation sequencing testing is dependent on pathologic diagnosis, tissue site, and diagnostic procedure. Understanding which specimens are at higher risk for failing molecular testing may help pathologists and clinical care teams optimize tissue acquisition and usage for patient care.


  • SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach

    by Alexander J. Neil, Lei Zhao, Raymond A. Isidro, Amitabh Srivastava, James M. Cleary, Fei Dong


  • Loss of functionSMAD4nonstop mutations in human cancer

    by Anna H Bauer, David W Basta, Jason L Hornick, Fei Dong

    Background: SMAD4is a tumour suppressor gene that is mutated in a variety of cancers.SMAD4nonstop mutations, which convert stop codons to sense codons that extend transcription, have been identified in genomic databases but have not been characterised in human pathology samples. The frequency ofSMAD4nonstop mutations and the consequences of nonstop mutations on SMAD4 protein expression are unknown.Methods: We retrospectively analysed our cancer sequencing database of 38,002 tumour specimens and evaluated the spectrum ofSMAD4mutations. SMAD4 protein expression was evaluated by immunohistochemistry in tumours withSMAD4nonstop mutations.Results: In total, 1956SMAD4mutations were identified in 1822 tumours.SMAD4mutations were most common in tumours of the gastrointestinal tract and included nonsense variants (n = 344), frameshift indels (n = 258), splice site variants (n = 104), and missense variants at codon R361 (n = 245). In a subset of cases with immunohistochemistry, SMAD4 expression was lost in 23 of 25 tumours (92%) with protein truncating variants and in 7 of 27 tumours (26%) with missense variants. Four cases harbouredSMAD4nonstop mutations.SMAD4nonstop mutations were identified in two pancreatic adenocarcinomas, one colonic adenocarcinoma, and one non‐small cell lung carcinoma. Immunohistochemistry demonstrated loss of SMAD4 protein expression in each of the four tumours withSMAD4nonstop mutations.Conclusion: SMAD4nonstop mutations are associated with loss of SMAD4 protein expression in multiple tumour types.SMAD4nonstop mutations should be clinically interpreted as pathogenic loss of function alterations when identified in cancer sequencing panels.